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Objective. Individuals with multiple metabolic risk factors often experience concomitant sleep-disordered breathing (SDB).
We aimed to determine the associations of SDB with individual components of metabolic syndrome independent of obesity.
Methods. A cross-sectional study was conducted in 1137 employees aged 30–64 years. Apnea-hypopnea index (AHI) was
assessed using a portable monitor for obstructive sleep apnea by admission. Of these, 451 participants took an oral glucose
tolerance test to assess homeostatic model assessment of insulin resistance (HOMA-IR) and Matsuda insulin sensitivity index
(ISI). Results. The odds ratio (OR) of the highest category of the AHI (≥15 episodes per hour) compared to the lowest
one (<5 episodes per hour) was signiﬁcantly elevated for hypertension, for hypertriglyceridemia, and for low HDL-
cholesterolemia when adjusted for age, sex, and alcohol and smoking status (p < 0 05). After further adjustment for body mass
index (BMI) or waist circumference, the associations for hypertension still remained statistically signiﬁcant (p < 0 05) while
those for hypertriglyceridemia and low HDL-cholesterolemia were no longer signiﬁcant. The association between higher insulin
resistance as assessed by HOMA-IR and Matsuda ISI and higher categories of the AHI was also lost after adjustment for BMI.
Conclusion. Obesity was a strong confounding factor in the association between SDB and most metabolic risk factors including
insulin resistance, except for hypertension. Further longitudinal study is needed to examine the temporal or causal relationships
between SDB and metabolic risk factors. This trial is registered with UMIN-CTR UMIN000028067.
1. Introduction
Obesity, particularly abdominal obesity, can cause individ-
uals to develop multiple metabolic disorders including
dyslipidemia, hyperglycemia, and/or hypertension. Clus-
tering of metabolic risk factors is not incidental, but
rather evidence of “metabolic syndrome” or “syndrome
X” [1]. Individuals with “syndrome X” often experience
concomitant sleep-disordered breathing (SDB) which acts
synergistically to increase their risk for cardiovascular dis-
ease [2, 3]. Thus, some investigators have suggested that
“syndrome X” may include SDB and must then be called
“syndrome Z” [4].
Recently, SDB has been reported to be independently asso-
ciated with metabolic syndrome [5, 6] and with its more fun-
damental factor, insulin resistance [7–9]. However, because
both SDB and metabolic derangements are strongly correlated
with indices of obesity, obesity becomes an important con-
founder in the relationship between SDB and metabolic
abnormalities. It is unknown whether SDB is causally related
to metabolic abnormalities or is just a bystander in the rela-
tionships between obesity and metabolic abnormalities.
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The aim of this study was to determine the associations of
SDB with individual components of metabolic syndrome
independent of obesity. The degrees of insulin resistance
were also examined in relation to the severity of SDB.
2. Materials and Methods
2.1. Participants. Participants included Japanese public
school employees who received medical checkups at the
Hokuriku Central Hospital between April 2006 and March
2010. On checkups, we recommended to take a sleep study
to employees with sleep-related symptoms of obstructive
sleep apnea including loud snoring, witnessed pauses in
breathing, restless sleep, morning headaches, and/or daytime
sleepiness or fatigue, unless they had already been treated for
sleep apnea syndrome. Also, excluded from the study were
those individuals who had <4 hours of quality data on record
or missing data. Additionally, some participants spent one
more night (total 2 nights) at the hospital and underwent
an oral glucose tolerance test (OGTT) after an overnight fast,
as previously reported [10]. Participants were considered
smokers if they smoked at least 1 cigarette per day. Alcohol
use was deﬁned by the number of days per week it was con-
sumed, regardless of the amount. Informed consent was
obtained via an opt-out method, and the Institutional Review
Board of the Kanazawa University approved the study proto-
col on June 21, 2017 (IRB no. 2497-1); the study protocol
conformed to the provisions of the Declaration of Helsinki.
The study was registered on the University Hospital Medical
Information Network Clinical Trials Registry (UMIN-CTR,
http://www.umin.ac.jp/ctr, UMIN ID: UMIN000028067).
2.2. Blood Sampling and Anthropometric Measurements.
After an overnight fast, blood samples were drawn from
the antecubital vein to measure triglycerides, high-density
lipoprotein (HDL) cholesterol, and fasting plasma glucose.
Triglycerides and HDL cholesterol were measured using
enzymatic analytical chemistry (Autoanalyzer BioMajesty
JCA-BM1650, JEOL Ltd., Tokyo, Japan), and plasma glucose
was assessed using the glucose oxidase method (Automatic
Glucose Analyzer ADAMSGlucose GA-1160, Arkray, Kyoto,
Japan) in the hospital laboratory. Insulin concentration
assays were performed by the chemiluminescence immuno-
assay method at a commercial laboratory (BML Inc., Tokyo,
Japan), with an intra-assay coeﬃcient of variation (CV) of
2.4–3.2% based on 10 replicates of 3 diﬀerent samples.
Resting blood pressure was measured in the sitting position
with an automatic device (Colin Model BP-203RV, Colin,
Tokyo, Japan) after ≥5 minutes of rest. Measurements of
body mass index (BMI) and waist circumference were con-
ducted according to published methods [11].
2.3. Assessment of Metabolic Risk Factors and Calculation
of Indices of Insulin Resistance. Participants were assessed
with metabolic risk factors according to the following deﬁni-
tions: hypertension, a systolic/diastolic blood pressure≥ 140/
90mmHg and/or taking antihypertensive medication;
hypertriglyceridemia, triglycerides≥ 150mg/dL (1.69mmol/
L); low HDL-cholesterolemia, <40mg/dL (1.04mmol/L) for
men and <50mg/dL (1.30mmol/L) for women; and impaired
fasting plasma glucose (IFG), ≥110mg/dL (6.1mmol/L)
[12]. Obesity was deﬁned by BMI≥ 25.0 kg/m2 according
to the Asian criterion of obesity [13]. The indices of
insulin resistance were as follows: Matsuda insulin sensi-
tivity index ISI = 10000/ Glu0 × Ins0 × Glu120 × Ins120 0 5
and homeostatic model assessment of insulin resistance
(HOMA-IR) =Glu0 × Ins0/405 [14], where Glux and Insy
represented values at time x or y (min) during the OGTT.
2.4. Sleep Study. Sleep studies were conducted at the Health
Check Department of Hokuriku Central Hospital for 1
night admission. Each participant’s apnea-hypopnea index
(AHI) was assessed using the PulSleep LS-100 (Fukuda
Denshi, Tokyo, Japan) which digitally records nasal airﬂow
via nasal cannula, oxygen saturation, and snoring sounds.
AHI was deﬁned as the average number of apneic plus
hypopneic episodes per hour of sleep. Apnea was deﬁned
as a complete cessation of nasal airﬂow, and hypopnea
was deﬁned as a decrease in nasal airﬂow of at least 50%
of baseline for ≥10 seconds. Both apnea and hypopnea
must be by ≥4% decrease in oxygen saturation [15].
2.5. Statistical Analysis. All analyses were conducted using
SPSS software version 24.0 for Windows (SPSS Inc., Chicago,
IL, USA). Participants were classiﬁed using the AHI at com-
monly used clinical cut-oﬀ points. Three severity gradients or
categories were used for the AHI in this study: none/minimal
(<5 episodes per hour (reference)), mild (≥5 but <15 per
hour), and moderate-to-severe (≥15 per hour). Data are pre-
sented as mean± SD values for continuous variables and as a
proportion for categorical variables. Tests to identify a linear
trend across categories were performed by assigning the
median value within each category and treating the catego-
ries as a continuous variable. Binary logistic regression anal-
yses were performed to estimate the adjusted odds ratio (OR)
for having metabolic risk factors in each category relative to
the reference category (AHI< 5.0). The following covariates
were used: age, sex, smoking (a 3-level variable: current,
former, and never smoker), and alcohol use (a 3-level var-
iable: drinking every day, drinking 1–6 days per week, and
drinking <1 day per week). First, these nonadipose covariates
were ﬁrst included in the regression model. Subsequently, to
assess whether the association between the stage of sleep dis-
order and each metabolic risk factor was independent of obe-
sity, either BMI or waist circumference was additionally
included in the model. Because the distribution of waist cir-
cumference was diﬀerent between men and women, waist
circumference was standardized to a mean of 0 and stan-
dard deviation of 1 in men and women, respectively, before
the inclusion in the multiple regression model. Finally, in
451 subjects undertaking the OGTT, the levels of HOMA-
IR and Matsuda ISI were compared among three diﬀerent
categories of the AHI. The comparisons were performed
before and after adjustments for BMI, using analysis of
covariance (ANCOVA). Analyses of HOMA-IR were con-
ducted after logarithmic transformation because of their
skewed distribution. A p value of <0.05 was considered statis-
tically signiﬁcant.
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3. Results
The overall study participants were composed of 1173 sub-
jects with a mean age of 51.1± 7.2 years and a mean BMI of
24.7± 3.5 kg/m2. Characteristics of the study participants
according to AHI categories are presented in Table 1. Com-
pared with those with lower AHI values, participants with
higher AHI values showed a signiﬁcantly higher proportion
of men and signiﬁcantly higher levels of BMI, blood pressure,
fasting plasma glucose, triglycerides, and HOMA-IR and
lower levels of HDL cholesterol and Matsuda ISI (p for the
trend< 0.01). The proportions of smokers, daily drinkers,
and those taking antihypertensive drugs were signiﬁcantly
higher in those with higher AHI values (p < 0 05).
Figure 1 shows the prevalence of metabolic abnormalities
by an AHI category stratiﬁed by obesity. For both strata, the
proportions of participants with hypertension and hypertri-
glyceridemia were signiﬁcantly higher in higher categories of
the AHI showed (p for the trend< 0.05). In participants with-
out obesity, the prevalence of low HDL-cholesterolemia and
hyperglycemia tended to be higher in higher categories of the
AHI but the trend test did not reach statistical signiﬁcance.
Table 2 shows the ORs for having individual risk factors
according to the level of sleep-disordered breathing. When
adjusted for age, sex, and alcohol and smoking status, the
ORs of the highest category of the AHI were signiﬁcantly ele-
vated for hypertension, for hypertriglyceridemia, and for low
HDL-cholesterolemia (p < 0 05). After further adjustment
for BMI, the associations for hypertension still remained sta-
tistically signiﬁcant (p < 0 05) while those for hypertriglyc-
eridemia and low HDL-cholesterolemia were no longer
signiﬁcant. The elevated ORs for hypertension in the highest
category of the AHI were also signiﬁcant after adjustments
for waist circumference in place of BMI (p < 0 05).
Finally, the levels of indices of insulin resistance were
compared among categories of the AHI in 451 subjects
(Figure 2). HOMA-IR was signiﬁcantly higher, and Matsuda
ISI was signiﬁcantly lower in higher categories of the AHI
(p for the trend< 0.01), but after adjusted for BMI, both indi-
ces no longer showed a signiﬁcant trend, indicating that the
association between AHI severity and insulin resistance was
confounded by BMI. Adjustments for waist circumference in
place of BMI showed similar results (data not shown). These
451 subjects took the OGTT not for any clinical signs but for
ﬁnancial reasons; they were slightly older (52.5± 6.7 yrs vs.
50.2± 7.4, p < 0 05), and the proportion of men was higher
(80.0% vs. 73.1%, p < 0 05) than those who did not take
the OGTT, but other characteristics including BMI was not
signiﬁcantly diﬀerent.
4. Discussion
In this study, the independent association between severity of
SDB and each metabolic risk factor was cross-sectionally
Table 1: Basic clinical characteristics of the study subjects according to the level of the apnea-hypopnea index (AHI).
Overall (N = 1173) AHI p for the trend<5.0 (N = 812) 5.0–15.0 (N = 250) ≥15.0 (N = 111)
Age (years) 51.1± 7.2 50.5± 7.3 52.9± 6.1 51.2± 8.0 0.02
Male gender (%) 75.8 69.5 86.4 98.2 <0.01
Anthropometries
Body mass index (BMI) (kg/m2) 24.7± 3.5 23.9± 3.0 25.8± 3.4 28.1± 4.6 <0.01
Obesity (%)∗ 40.1 31.0 56.4 69.4 <0.01
Waist circumference (cm) in men 86.5± 8.8 84.2± 7.5 89.0± 8.2 93.5± 10.6 <0.01
Waist circumference (cm) in women 81.5± 9.4 80.8± 8.9 86.1± 11.6 93.5± 13.4 <0.01
Metabolic parameters
Systolic blood pressure (mmHg) 131.5± 19.0 128.4± 18.0 135.7± 17.9 144.6± 21.4 <0.01
Diastolic blood pressure (mmHg) 82.0± 11.8 80.1± 11.3 84.7± 11.2 89.8± 11.8 <0.01
Fasting plasma glucose (mg/dL) 100.8± 17.9 99.8± 18.4 102.8± 17.4 103.6± 15.2 0.01
Triglycerides (mg/dL) 78/109/156 73/102/145 85/125/184 104/146/193 <0.01
HDL cholesterol (mg/dL) 58.0± 14.2 60.0± 14.8 54.4± 12.4 51.4± 9.9 <0.01
HOMA-IR (N = 451) 0.8/1.0/1.5 0.7/1.0/1.4 0.8/1.1/1.7 1.0/1.4/2.1 <0.01
Matsuda ISI (N = 451) 11.0± 8.7 12.0± 8.9 10.0± 9.0 7.3± 4.9 <0.01
Habits
Smokers (%) 19.6 18.1 22.0 25.2 0.04
Daily drinkers (%) 33.7 31.9 36.0 41.4 0.03
Taking medications
Antihypertensive drugs (%) 15.0 12.6 17.2 27.9 <0.01
Lipid-lowering drugs (%) 7.5 6.5 10.4 8.1 0.24
Glucose-lowering drugs (%) 4.1 3.6 5.2 5.4 0.24
Data are expressed as mean ± SD, 25/50/75th percentile value, or number (%). ∗Obesity was deﬁned by BMI ≥ 25.0 kg/m2. HDL cholesterol: high-density
lipoprotein cholesterol; HOMA-IR: homeostatic model assessment of insulin resistance; Matsuda ISI: Matsuda insulin sensitivity index.
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Figure 1: Prevalence of metabolic abnormalities by an AHI category stratiﬁed by obesity, using BMI≥ 25.0 kg/m2 as a cut-oﬀ.
#Hyperglycemia was deﬁned as fasting plasma glucose≥ 110mg/dL (6.1mmol/L) and/or taking medications for diabetes. AHI: apnea-
hypopnea index; BMI: body mass index; HDL: high-density lipoprotein; NS: not statistically signiﬁcant.
Table 2: Multivariable analysis for metabolic abnormalities according to the apnea-hypopnea index (AHI) category.
Odds ratios (95% CI) by an AHI category
<5.0 (N = 812) 5.0–15.0 (N = 250) ≥15.0 (N = 111)
Hypertension
Crude 1.0 1.9 (1.4–2.6)∗ 4.2 (2.7–6.3)
Multivariable-adjusted† 1.0 1.6 (1.2–2.1) 3.6 (2.3–5.6)
Multivariable and BMI-adjusted 1.0 1.1 (0.8–1.6) 1.9 (1.2–3.1)
Multivariable and waist-adjusted 1.0 1.1 (0.8–1.6) 2.1 (1.3–3.3)
Hypertriglyceridemia‡
Crude 1.0 1.9 (1.4–2.5) 3.1 (2.1–4.7)
Multivariable-adjusted 1.0 1.6 (1.1–2.2) 2.4 (1.6–3.7)
Multivariable and BMI-adjusted 1.0 1.1 (0.8–1.6) 1.3 (0.8–2.0)
Low HDL-cholesterolemia
Crude 1.0 1.4 (0.8–2.3) 1.8 (1.0–3.5)
Multivariable-adjusted 1.0 1.5 (0.9–2.6) 2.2 (1.1–4.4)
Multivariable and BMI-adjusted 1.0 1.2 (0.7–2.1) 1.4 (0.6–2.9)
Hyperglycemia‡
Crude 1.0 1.2 (0.8–1.8) 1.9 (1.2–3.0)
Multivariable-adjusted 1.0 1.0 (0.7–1.5) 1.6 (1.0–2.6)
Multivariable and BMI-adjusted 1.0 0.7 (0.4–1.0) 0.7 (0.4–1.2)
∗Bold font indicates that the odds ratio is statistically signiﬁcant (p < 0 05). †Multivariable model adjusted for age, sex, alcohol intake, and smoking
status. ‡Hyperglycemia was deﬁned as fasting plasma glucose ≥ 110mg/dL (6.1mmol/L) and/or taking medications for diabetes. BMI: body mass index;
CI: conﬁdence interval.
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examined in middle-aged Japanese men and women. After
controlling for obesity, independent association was found
for hypertension but not for dyslipidemia, hyperglycemia,
and insulin resistance. These results suggest that SDB is
an independent determinant for hypertension but may be
only a bystander in the link between obesity and other
metabolic abnormalities.
The link between SDB and hypertension was indepen-
dent of obesity in this study, consistent with large
community-based studies [6, 16, 17] and several randomized
trials [18]. Their link was maintained after adjustment for
waist circumference, an index of abdominal obesity, as well
as BMI, an index of generalized obesity. In the CIRCS study,
which demonstrated an independent association between
SDB and metabolic syndrome in nonoverweight Japanese,
the OR for hypertension in subjects with ≥15 hypoxia
events/hour was highest (OR, 2.5; 95% CI, 1.4–4.6) among
ORs for all components of metabolic syndrome [19]. Their
results are in line with our observation that the OR for
hypertension was only signiﬁcantly elevated after control-
ling for obesity but not those for other metabolic risk fac-
tors. Although the eﬀects of SDB on blood pressure have
been reported to be weakened in elder subjects, at least
in relatively younger subjects including our population,
SDB seems to be an independent contributor to elevated
blood pressure beyond obesity.
The association between hypertriglyceridemia and
higher categories of the AHI was disappeared after adjust-
ments for BMI in this study. There have been two large
studies demonstrating an association between SDB and
metabolic syndrome conducted in Japan [5, 6]. However,
looked into the individual components of metabolic syn-
drome in these studies, after controlling for concomitant
obesity, the association between hypertriglyceridemia and
severity of SDB was diminished in one study [5] and was
maintained only in nonoverweight subjects in the other
with OR of 1.7 and 95% CI of 1.0–2.8 [6]. Moreover, the
eﬀects of OSA-targeted therapeutic intervention using
CPAP on the lipid proﬁle are controversial among investi-
gators [20]. A metaregression analysis including 29 studies
with 1958 subjects has concluded that CPAP treatment
for OSA decreased total cholesterol and LDL cholesterol
and did not aﬀect TG levels [21]. Because hypertriglyc-
eridemia is the strongest correlate with abdominal obesity
among metabolic risk factors [22], the magnitude of associ-
ation independent of obesity, if any, appears to be small rel-
ative to other components such as hypertension.
The prevalence of hyperglycemia, as assessed by fasting
plasma glucose ≥110mg/dL, was not signiﬁcantly increased
in higher categories of the AHI after controlling for BMI,
consistent with prior studies [5, 6, 23]. The association
between IFG and SDB was insigniﬁcant after adjustments
for anthropometric indices in 1344 subjects from the
Korean genome and epidemiology study [23] and in a male
working population [5]. Although some prospective studies
have demonstrated that SDB independently preceded and
predicted the development of type 2 diabetes [19, 24, 25],
even in these cases, the cross-sectional associations at base-
line between SDB and diabetes after controlling for BMI
[19, 25] and between SDB and fasting glucose levels [24]
were not signiﬁcant.
Why was the independent association between metabolic
risk factors and SDB not seen in our study? In the CIRCS
Study, the association between glucose abnormality and
SDB after controlling for BMI was signiﬁcant only in over-
weight subjects with OR of 1.6 and 95% CI of 1.0–2.6 and
not in nonoverweight individuals with OR of 1.4 and 95%
CI of 0.8–2.5 [6]. In study populations composed of less over-
weight subjects like this study, it may be diﬃcult to detect the
independent association between glucose abnormality and
SDB. Further study is needed, comprising subjects without
obesity and with SDB.
Furthermore, we failed to show the higher levels of
insulin resistance in relation to severity of AHI categories
after controlling for BMI. The discordance with prior epi-
demiological and clinical studies [7–9] may be attributed
to relatively younger age of our study subjects. Because obe-
sity is a major determinant of insulin resistance in younger
subjects, a marginal inﬂuence of SDB in insulin resistance
would be diﬃcult to be demonstrated. Confounding eﬀects
of obesity also render it diﬃcult to demonstrate an inde-

























































Figure 2: Unadjusted and BMI-adjusted indices of insulin
resistance by an AHI category. HOMA-IR was log-transformed
prior to analysis to reduce skewedness, and calculated values were
untransformed after analysis. Error bars show standard error of
the mean. AHI: apnea-hypopnea index; BMI: body mass index;
HOMA-IR: homeostatic model assessment of insulin resistance.
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a study of 40 treatment-naïve, nondiabetic German sub-
jects, insulin sensitivity as assessed by a hyperinsulinemic
euglycemic clamp was not signiﬁcantly improved in
patients with obesity [26]. Negative eﬀects of CPAP therapy
on insulin resistance have been also reported in two previ-
ous randomized controlled trials in patients with obesity
[27, 28] and in a recent meta-analysis [29].
The strength of this study was the simultaneous evalua-
tion of multiple metabolic risk factors in relation to the sever-
ity of SDB, but several limitations should be considered. First,
the measurement of blood pressure was performed approxi-
mately at 9 o’clock in the daytime. Sasaki et al. reported that
approximately half the OSAS patients displayed morning
hypertension [30], which may be missed by our evaluation.
Second, insulin resistance was not measured by the glucose
clamp technique, which is the gold standard for evaluating
insulin resistance/sensitivity; however, it has been demon-
strated that Matsuda ISI and HOMA-IR correlated well with
directly measured insulin resistance and with metabolic
abnormalities in nondiabetic subjects [31]. Third, obesity
was assessed only by BMI and waist circumference. However,
these two anthropometric indices are not inferior to visceral
adipose tissue in correlation with insulin resistance [32] or
with blood pressure [22] in Japanese men and women.
Fourth, the sleep device in this study did not measure chest
or abdomen movements, by which the strict diﬀerentiation
between obstructive and central type of SDB was diﬃcult.
Finally, the cross-sectional design does not allow examina-
tion of the temporal or causal relationships between SDB
and metabolic risk factors. Longitudinal studies are needed
to conﬁrm whether SDB is one of the secondary causes of
incident hypertension in this population.
In conclusion, the cross-sectional associations of SDB
with metabolic abnormalities vary across the individual risk
factors. Obesity was a strong confounding factor in the asso-
ciation between SDB and most metabolic risk factors includ-
ing insulin resistance. However, for hypertension, SDB had
an independent association beyond confounding eﬀects of
obesity. Further longitudinal study is needed to examine the
temporal or causal relationships between SDB and metabolic
risk factors.
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